# thermoscientific The scientific thermoscientific thermos

## COVID-19 and scarce hospital resources

Thermo Scientific<sup>™</sup> B·R·A·H·M·S MR-proADM<sup>™</sup> KRYPTOR<sup>™</sup> for risk stratification to support decisions on the required level of care



Test MR-proADM on presentation to the ED

MR-proADM as an aid to assess early the risk for progression to a more severe disease condition and decide on **safe discharge or hospital admission** 

< 0.87 nmol/L

Low risk for progression

to a more severe disease condition, i.e. safe discharge possible<sup>1</sup>



during ICU stay

MR-proADM as an aid to accurately monitor disease severity

<2.25 nmol/L

**Safe discharge of clinically stable patients** from the ICU to a lower level of care possible<sup>2</sup>

>0.87 nmol/L

**Elevated risk for progression** 

to a more severe disease condition, hospital admission recommended <sup>1</sup>



Thermo Fisher SCIENTIFIC

### **thermo**scientific

Integration of B·R·A·H·M·S MR-proADM KRYPTOR into clinical risk assessment improves clinical decision making on level of care and use of scarce hospital resources



#### In the ED

Stratify patients according to severity of disease to outpatient, hospital or ICU care



#### In the ICU

Identify clinically stable patients who can be discharged from the ICU to a lower level of care, thereby making more efficient use of limited ICU resources



References: 1. Saeed et al., Critical Care 2019; 23: 40. 2. Elke et al., Crit Care 2018; 22(1): 79. doi: 10.1186/s13054-018-2001

**Clinical Diagnostics** 

Thermo Fisher Scientific B·R·A·H·M·S GmbH Neuendorfstr. 25 16761 Hennigsdorf Germany +49 (0)3302 883 0 +49 (0)3302 883 100 fax info.brahms@thermofisher.com www.thermoscientific.com/brahms



#### Find out more at thermoscientific.com/proadrenomedullin

Product is CE marked but not 510(k)-cleared and not available for sale in the U.S. Availability of product in each country depends on local regulatory marketing authorization status.

